Business
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
-- With fertility rates at historic lows, Femasys advances access to early infertility care through FemaSeed® Complete, enabling OB/GYNs to treat patients within their own practices --ATLANTA, May 08, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announces its financial results for the quarter ended March 31, 2026 and provides a corporate update.
About this update from Femasys Inc.
[{"type":"image","alt":"Femasys Inc.","displaySize":"","headline":null,"caption":"Femasys Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":122,"url":"https://media.zenfs.com/en/globenewswire.com/301b83514d43baad2f5211eaa290a825"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2GAPMaOqvqggyHfSDG8ZUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MQ--/https://media.zenfs.com/en/globenewswire.com/301b83514d43baad2f5211eaa290a825","width":300,"height":122},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/2GAPMaOqvqggyHfSDG8ZUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MQ--/https://media.zenfs.com/en/globenewswire.com/301b83514d43baad2f5211eaa290a825","width":300,"height":122}},"lazy":false},{"type":"text","content":"-- With fertility rates at historic lows, Femasys advances access to early infertility care through FemaSeed® Complete, enabling OB/GYNs to treat patients within their own practices --","length":184,"tagName":"p"},{"type":"text","content":"ATLANTA, May 08, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announces its financial results for the quarter ended March 31, 2026 and provides a corporate update.","length":322,"tagName":"p"},{"type":"text","content":"Corporate Highlights from 1Q 2026 to date","length":41,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Advanced initial commercial adoption of FemaSeed Complete, positioning Femasys to expand access to first-line fertility treatment through integrated, in-office care by OB/GYNs, supporting earlier intervention prior to referral to higher-cost specialty care.","length":257,"tagName":"p"}]},{"val":[{"type":"text","content":"Launched FemaSeed Complete at ACOG 2026, advancing commercialization and expanding provider awareness to support adoption of first-line fertility treatment in the OB/GYN office.","length":177,"tagName":"p"}]},{"val":[{"type":"text","content":"Established strategic partnership with AMI Technologies to introduce and commercialize its fertility portfolio in Israel, expanding international market opportunities.","length":172,"tagName":"p"}]},{"val":[{"type":"text","content":"Appointed John Canning as Chief Operating Officer, enhancing leadership to drive operat...